Pharmacological agents for the treatment of urinary incontinence due to overactive bladder

Expert Opinion on Investigational Drugs

Volumn 10, Issue 1, 2001, Pages 65-83

  Wein, A J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anticholinergic agents; Muscarinic receptor antagonists; Overactive bladder; Oxybutynin; Tolterodine; Trospium chloride; Urinary incontinence

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCHOLINE; ADENYLATE CYCLASE; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DARIFENACIN; DOPAMINE RECEPTOR; GLUTAMINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; OPIATE RECEPTOR; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; PURINE P2X RECEPTOR; RECEPTOR; RESINIFERATOXIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TACHYKININ RECEPTOR ANTAGONIST; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

ANTICHOLINERGIC EFFECT; BLADDER; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CONSTIPATION; DESENSITIZATION; DETRUSOR MUSCLE; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; MICTURITION REFLEX; MUSCLE CONTRACTION; NERVE ENDING; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PERIPHERAL NERVOUS SYSTEM; REVIEW; SENSORY NERVE; SOMNOLENCE; TACHYCARDIA; URINE INCONTINENCE; VISUAL IMPAIRMENT; XEROSTOMIA;

CHOLINERGIC ANTAGONISTS; HUMANS; SEROTONIN ANTAGONISTS; URINARY BLADDER; URINARY BLADDER DISEASES; URINARY INCONTINENCE;

EID: 0035184357     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.1.65     Document Type: Review

References (69)

1. Advances in the pharmacological control of the bladder
2. Epidemiology, pathophysiology and evaluation of urinary incontinence and overactive bladder
3. A neurologic basis for the overactive bladder
4. A myogenic basis for the overactive bladder
5. Recent approaches to the treatment of urinary incontinence
6. Muscarinic receptor antagonists in the treatment of overactive bladder
7. Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle
8. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins
9. Characterization of the functional muscarinic receptors in the rat urinary bladder
10. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo
11. Pharmacologic options for the overactive bladder
12. 1-adrenoceptors and bladder function
13. 1a-subtype
14. 1-adrenoceptor antagonists
15. 1-adrenoceptors in urethral function
16. Comparison of the effects of various spasmolytic drugs on isolated human and porcine detrusor smooth muscle
17. Initial clinical experience with the selective phosphodiesterase (PDE)-1 isoenzyme-inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder
18. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro
19. Autoradiographic localization of tachykinin and calcitonin gene-related peptide receptors in adult urinary bladder
20. Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate
21. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves
22. The mammalian tachykinin receptors
23. Calcium dependent K-channels in guinea pig and human urinary bladder
24. K-channel opening activity of ZD6169 and its analogs: Effect on 86Rb efflux and 3H-P1075 binding in bladder smooth muscle
25. Effects of pinacidil on detrusor instability in men with bladder outlet obstruction
26. The effect of levcromakalim (BRL38227) on bladder function in patients with high spinal cord lesions
27. ZENECA ZD-6169: A novel KATP channel opener with in vivo selectivity for urinary bladder
28. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues
29. Calcium regulation of urinary bladder function
30. Effects of nifedipine on the smooth muscle of the human urinary tract in vitro and in vivo
31. Clinical relevance of some findings in neuro-anatomy and neurophysiology of the lower urinary tract
32. The effects of Bay K 8644 and nifedipine on the responses of rat urinary bladder to electrical field stimulation, beta, gamma-methylene ATP and acetylcholine
33. Effect of nifedipine on the contractile responses of the isolated rat bladder
34. LY227942, an inhibitor of serotonin and norepinephrine uptake: Biochemical pharmacology of a potential antidepressant drug
35. Effect of several 5-hydroxytryptamine(1A) receptor ligands on the micturition reflex in rats: Comparison with WAY 100635
36. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: Expression and function in humans
37. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists
38. Tolterodine - A new bladder-selective antimuscarinic agent
39. Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor over-activity
40. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
41. Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist
42. Once-daily tolterodine treatment significantly decreases perception of urgency and urge incontinence episodes in patients with overactive bladder
43. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin
44. Pharmacological treatment of urinary incontinence
45. Controlled release oxybutynin maintains efficacy with a 43% reduction in side effects compared with conventional oxybutynin treatment
46. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients
47. Medical treatment and medical side effects in urinary incontinence in the elderly
48. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial
49. High-dose trospium chloride in therapy of detrusor hyperreflexia
50. Trospium chloride versus oxybutynin: A randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia
51. Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test
52. R and S enantiomers of oxybutynin: Pharmacological effects in guinea pig bladder and intestine
53. Discovery and development of selective M3 antagonists for clinical use
54. Muscarinic antagonists in development for disorders of smooth muscle function
55. The effects of single dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability
56. Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency
57. Inhibitory effects of NS-21, a novel drug for urinary incontinence and its active metabolite, RCC-36, on L-type calcium currents in isolated guinea pig detrusor smooth muscle cells
58. Anticholinergic and calcium antagonistic activities of NS-21 contribute to the inhibition of rat urinary bladder contractions
59. Effect of the anticholinergic drug with calcium antagonistic activity, (±)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate, on dogs
60. Effect of the anticholinergic drug with calcium antagonistic activity, (±)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate, on monkeys
61. Torsades de pointes ventricular tachycardia and terodiline
62. Synthesis and antimuscarinic activity of a series of 4-(1-imidazolyl)-2,2-diphenylbutyramides: Discovery of potent and subtype-selective antimuscarinic agents
63. Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenylylcarbamate derivatives
64. Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus
65. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat
66. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor
67. Intestinal tolerability of nitroxybutyl-flurbiprofen in rats
68. Protective effect of NO on gastric lesions and inhibition of expression of gastric inducible NOS by flurbiprofen and its nitro-derivative, nitroflurbiprofen
69. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice